mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Abstract mRNA technologies have recently proven clinical efficacy against coronavirus disease 2019 and are among the most promising technologies to address the current pandemic. Here, we show preclinical data for our clinical candidate CVnCoV, a lipid nanoparticle-encapsulated mRNA vaccine that enco...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Susanne Rauch, Nicole Roth, Kim Schwendt, Mariola Fotin-Mleczek, Stefan O. Mueller, Benjamin Petsch
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cd8e43991c174e7d889fac0b807b0efe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd8e43991c174e7d889fac0b807b0efe
record_format	dspace
spelling	oai:doaj.org-article:cd8e43991c174e7d889fac0b807b0efe2021-12-02T18:03:46ZmRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents10.1038/s41541-021-00311-w2059-0105https://doaj.org/article/cd8e43991c174e7d889fac0b807b0efe2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00311-whttps://doaj.org/toc/2059-0105Abstract mRNA technologies have recently proven clinical efficacy against coronavirus disease 2019 and are among the most promising technologies to address the current pandemic. Here, we show preclinical data for our clinical candidate CVnCoV, a lipid nanoparticle-encapsulated mRNA vaccine that encodes full-length, pre-fusion stabilised severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. In contrast to previously published approaches, CVnCoV is exclusively composed of naturally occurring nucleotides. Immunisation with CVnCoV induced strong humoral responses with high titres of virus-neutralising antibodies and robust T-cell responses. CVnCoV vaccination protected hamsters from challenge with wild-type SARS-CoV-2, demonstrated by the absence of viral replication in the lungs. Hamsters vaccinated with a suboptimal dose of CVnCoV leading to breakthrough viral replication exhibited no evidence of vaccine-enhanced disease. Overall, data presented here provide evidence that CVnCoV represents a potent and safe vaccine candidate against SARS-CoV-2.Susanne RauchNicole RothKim SchwendtMariola Fotin-MleczekStefan O. MuellerBenjamin PetschNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Susanne Rauch Nicole Roth Kim Schwendt Mariola Fotin-Mleczek Stefan O. Mueller Benjamin Petsch mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
description	Abstract mRNA technologies have recently proven clinical efficacy against coronavirus disease 2019 and are among the most promising technologies to address the current pandemic. Here, we show preclinical data for our clinical candidate CVnCoV, a lipid nanoparticle-encapsulated mRNA vaccine that encodes full-length, pre-fusion stabilised severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. In contrast to previously published approaches, CVnCoV is exclusively composed of naturally occurring nucleotides. Immunisation with CVnCoV induced strong humoral responses with high titres of virus-neutralising antibodies and robust T-cell responses. CVnCoV vaccination protected hamsters from challenge with wild-type SARS-CoV-2, demonstrated by the absence of viral replication in the lungs. Hamsters vaccinated with a suboptimal dose of CVnCoV leading to breakthrough viral replication exhibited no evidence of vaccine-enhanced disease. Overall, data presented here provide evidence that CVnCoV represents a potent and safe vaccine candidate against SARS-CoV-2.
format	article
author	Susanne Rauch Nicole Roth Kim Schwendt Mariola Fotin-Mleczek Stefan O. Mueller Benjamin Petsch
author_facet	Susanne Rauch Nicole Roth Kim Schwendt Mariola Fotin-Mleczek Stefan O. Mueller Benjamin Petsch
author_sort	Susanne Rauch
title	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
title_short	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
title_full	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
title_fullStr	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
title_full_unstemmed	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
title_sort	mrna-based sars-cov-2 vaccine candidate cvncov induces high levels of virus-neutralising antibodies and mediates protection in rodents
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/cd8e43991c174e7d889fac0b807b0efe
work_keys_str_mv	AT susannerauch mrnabasedsarscov2vaccinecandidatecvncovinduceshighlevelsofvirusneutralisingantibodiesandmediatesprotectioninrodents AT nicoleroth mrnabasedsarscov2vaccinecandidatecvncovinduceshighlevelsofvirusneutralisingantibodiesandmediatesprotectioninrodents AT kimschwendt mrnabasedsarscov2vaccinecandidatecvncovinduceshighlevelsofvirusneutralisingantibodiesandmediatesprotectioninrodents AT mariolafotinmleczek mrnabasedsarscov2vaccinecandidatecvncovinduceshighlevelsofvirusneutralisingantibodiesandmediatesprotectioninrodents AT stefanomueller mrnabasedsarscov2vaccinecandidatecvncovinduceshighlevelsofvirusneutralisingantibodiesandmediatesprotectioninrodents AT benjaminpetsch mrnabasedsarscov2vaccinecandidatecvncovinduceshighlevelsofvirusneutralisingantibodiesandmediatesprotectioninrodents
_version_	1718378713301647360

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Ejemplares similares